Products & Services
Biosimilar Monoclonal Antibodies (mAbs)
At CLONOVA, we are at the forefront of developing biosimilar monoclonal antibodies (mAbs) using cutting-edge genetic engineering tools and innovative bioprocess technologies across both upstream and downstream platforms. Our goal is to deliver high-quality, affordable biologics that meet rigorous global standards of safety, efficacy, and consistency.
Biosimilars play a crucial role in enhancing patient access to life-saving therapies while reducing the overall cost of healthcare, particularly in the treatment of oncological, autoimmune, and other complex chronic diseases.
With a strong commitment to innovation and quality, CLONOVA is building a robust pipeline of monoclonal antibodies designed for global reach. Our flexible partnering model enables strategic collaborations with international pharmaceutical companies, healthcare providers, and research institutions — ensuring faster development, efficient commercialization, and broader patient impact worldwide.
Exosome-Based Therapeutics and Technologies
Exosomes are rapidly emerging as transformative tools in clinical medicine, offering innovative solutions for diagnostics, targeted drug delivery, and regenerative therapies.
These naturally derived, nanoscale vesicles carry proteins, lipids, and genetic material between cells, enabling precise delivery of therapeutic agents or genes to diseased tissues — including those affected by cancer and neurodegenerative disorders.
In regenerative medicine, stem cell–derived exosomes play a vital role in tissue repair and inflammation modulation, enhancing recovery in conditions such as orthopedic injuries, cardiac, and pulmonary diseases. Their application as biomarkers further supports non-invasive disease detection and real-time monitoring.
While the potential of exosome-based therapies is immense, scalable manufacturing and regulatory standardization remain critical for clinical translation.
At CLONOVA, we are advancing the field with a novel exosome manufacturing process utilizing STR single-use bioreactors through a suspension cell culture platform — enabling consistent, scalable, and high-quality exosome production for therapeutic and diagnostic applications.